An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone who previously lost about 20 pounds on semaglutide (the drug in Wegovy) switched to tirzepatide and is asking at what dose people start to feel appetite suppression and stop thinking about food. They report getting their third weekly injection of tirzepatide at 5 mg and so far feeling nothing different — no nausea or other side effects, and their appetite and “food noise” (constant thoughts about eating) remain. They’re sticking to their diet and workouts and wondering if this is normal or if the dose needs to be higher or simply more time. Tirzepatide is a newer injectable medication for weight loss and diabetes that works differently from semaglutide. Semaglutide mimics a hormone from the gut that tells your brain you’re full and slows digestion. Tirzepatide does that too, but it also activates a second gut hormone pathway, so people call it a “dual” drug. That dual action can make its effects on appetite and blood sugar stronger for some people. Both drugs are prescription medicines given by injection, and they’re usually started at low doses that are slowly increased to limit side effects. What this personal report actually shows is an early-stage, single-person observation: three shots in and no noticeable effect. Clinical trials of tirzepatide showed meaningful average weight loss over months, but people don’t all respond the same way. It’s common for the drug’s effects to build over several weeks as the dose is increased. Side effects like nausea sometimes appear early and then fade; conversely, lack of side effects doesn’t mean the drug isn’t working later. The real clinical studies that led to approval measured outcomes over many weeks and at higher maintenance doses than 5 mg, so a single person’s short-term experience can’t tell us how well it will work long term for them. Why this matters is practical: if you or someone you know has switched from semaglutide to tirzepatide, expectations and timing are important. You may not feel appetite suppression immediately, especially at low starting doses. People who care most are those trying to manage weight or blood sugar and who want to know whether to keep going, change dose, or switch treatments. This report underscores the need for patience and close follow-up with a prescribing clinician, who can advise on the typical titration schedule (gradual dose increases) and what to expect. Caveats: this is an anecdote, not a controlled study. Some people experience side effects like nausea, diarrhea, or low blood sugar with these medications. They aren’t safe or appropriate for everyone — people with certain medical histories (for example, a personal or family history of certain thyroid cancers) may be advised against them. Dosing plans and safety monitoring should come from a doctor. If someone has little effect after a few weeks at a low dose, the usual next step is to discuss continuing the planned dose escalation rather than jump to conclusions about failure. Bottom line: Early lack of appetite change after a few weeks on a low dose of tirzepatide can be normal; most evidence for its effectiveness comes from longer trials at higher doses, so stay in touch with your clinician about the titration plan and what to expect next.
Source: r/Semaglutide